Palisade Bio (PALI) Times Interest Earned (2010 - 2026)
Palisade Bio (PALI) posted quarterly Times Interest Earned of -$10748.0 for Q1 2026, down 365.28% year-over-year from $4051.5 in Q1 2025, and down 438.42% quarter-over-quarter from -$1996.2 in Q4 2025.
Palisade Bio (PALI) Times Interest Earned (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Times Interest Earned for 17 consecutive years, with -$10748.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 365.28% year-over-year to -$10748.0; the TTM figure through Mar 2026 stood at -$2038.0 (down 111.41% YoY), while the FY2025 annual figure was -$0.66, down 44.59% from the prior year.
- Times Interest Earned declined to -$10748.0 in Q1 2026 per PALI's latest filing, from -$1996.2 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.07 in Q1 2023 and bottomed at -$10748.0 in Q1 2026.
- Historically, Times Interest Earned has averaged -$1367.3 across 5 years, with a median of -$584.4 in 2025.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 99.92% — and 2024, when it sank 398112.77%.
- Palisade Bio's Times Interest Earned stood at -$1924.0 in 2022, then jumped by 59.02% to -$788.5 in 2023, then increased by 28.51% to -$563.67 in 2024, then sank by 254.15% to -$1996.2 in 2025, then plunged by 438.42% to -$10748.0 in 2026.
- Business Quant data shows PALI's Times Interest Earned at -$10748.0 in Q1 2026, -$1996.2 in Q4 2025, and -$584.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,748.00 |
| Dec 31, 2025 | -1,996.20 |
| Sep 30, 2025 | -584.40 |
| Jun 30, 2025 | -1,421.50 |
| Mar 31, 2025 | -2,310.00 |
| Dec 31, 2024 | -563.67 |
| Sep 30, 2024 | -598.83 |
| Jun 30, 2024 | -467.89 |
| Mar 31, 2024 | -282.54 |
| Dec 31, 2023 | -788.50 |
| Sep 30, 2023 | -157.42 |
| Jun 30, 2023 | -1,203.00 |
| Mar 31, 2023 | -0.07 |
| Dec 31, 2022 | -1,924.00 |
| Sep 30, 2022 | -53.82 |
| Jun 30, 2022 | -54.12 |
| Mar 31, 2022 | -90.42 |
| Dec 31, 2021 | 1.73 |
| Sep 30, 2021 | -116.00 |
| Jun 30, 2021 | -50.16 |